- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04107103
Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma (NivoPlus)
A Study to Evaluate the Safety and Feasibility of the Combined Use of Nivolumab With Pemetrexed for the Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Hatim Karachiwala, MD FRCPC
- Phone Number: 780-832-8290
- Email: hatim.karachiwala@ahs.ca
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada
- Recruiting
- Cross Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must be 18 years of age or older.
- Patients must have a diagnosis of histologically confirmed squamous cell carcinoma of the head and neck not amenable to curative intent therapy (surgery or radical chemoradiation).
- Patients with squamous cell cancer of the head and neck (SCCHN) who either have a recurrence within 6 months of potentially curative neoadjuvant/adjuvant platinum-based therapy or recurrence after receiving plantium based therapy in a non-curative setting, and who have a good performance status. Nivolumab may also be considered for patients who are ineligible for a platinum-based chemotherapy.
- Patients presenting with a diagnosis of HPV-related (p16+) squamous cell carcinoma without an unknown primary will be eligible for enrolment if the investigator deems a head and neck primary to be the most likely primary source.
- Patients must be capable of providing consent to enrolment and treatment.
- Patients with a performance status of ECOG 0-2(15) will be eligible for enrolment (see appendix 1).
- Measurable disease must be present according to RECIST criteria V1.1(16) (see appendix 5).
- Women of child bearing potential (WOCBP) must have a negative serum (or urine) pregnancy test at the time of screening. WOCBP is defined as any female who has experienced menarche and who has not undergone surgical sterilization (hysterectomy or bilateral oophorectomy or bilateral salpingectomy) and is not postmenopausal. Menopause is defined as 12 months of amenorrhea in a woman over age 45 years in the absence of other biological or physiological causes.
Patients (men and women) of childbearing / reproductive potential should use highly effective birth control methods, as defined by the investigator, during the study treatment period and for a period of 6 months after the last dose of study drug. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly.
- Note: abstinence is acceptable if this is established and preferred contraception for the patient and is accepted as a local standard.
- Female patients who are breast-feeding should discontinue nursing prior to the first dose of study treatment and until 30 days after the last dose of study drug.
- Male patients should agree to not donate sperm during the study and for a period of at least 6 months after last dose of study drug.
- Absence of any condition hampering compliance with the study protocol and follow- up schedule; those conditions should be discussed with the patient before registration in the trial.
- The following adequate organ function laboratory values must be met:
Hematological:
- Absolute neutrophil count (ANC) >1.5 x109/L
- Platelet count >100 x109/L
- Hemoglobin >9 g/dL (may have been transfused)
Renal:
-Estimated creatinine clearance ≥ 45 mL/min according to the Cockcroft-Gault formula (or l-ocal institutional standard method)
Hepatic:
- Total serum bilirubin <1.5x ULN
- AST and ALT <2.5x ULN (or ≤ 5 x ULN for patients with documented metastatic disease to the liver)
Exclusion Criteria:
- History of pneumonitis requiring treatment with steroids.
- History of active interstitial lung disease.
- Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 months prior to enrollment), unstable angina, congestive heart failure (≥ New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication.
History of another malignancy or a concurrent malignancy;
-Exceptions include patients who have been disease-free for 3 years, or patients with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ.
Active brain metastases or leptomeningeal disease.
-Patients with treated brain metastases that are stable for 6 weeks will be eligible for enrolment.
- Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication).
- Prior organ transplantation including allogeneic stem-cell transplantation.
- Active autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Patients with diabetes type I, vitiligo, psoriasis, or hypo- or hyperthyroid diseases not requiring immunosuppressive treatment are eligible.
- Active infection requiring systemic therapy.
- Known prior severe hypersensitivity to investigational product or any component in its formulations, including known severe hypersensitivity reactions to monoclonal antibodies (CTCAE v4.03 Grade ≥ 3).
- Other severe acute or chronic medical conditions including inflammatory bowel disease, immune pneumonitis, pulmonary fibrosis or psychiatric conditions including recent (within the past year) or active suicidal ideation or behavior; or laboratory abnormalities that may increase the risk associated with study participation or study treatment administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for entry into this study.
- Persisting toxicity related to prior therapy (NCI CTCAE v. 4.03 grade > 1); however, alopecia, sensory neuropathy ≤ grade 2, or other toxicities ≤ grade 2 not constituting a safety risk based on investigator's judgment are acceptable.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Single Arm
A single-arm combining nivolumab with pemetrexed
|
Nivolumab 3 mg/kg IV q.2 weekly in combination with pemetrexed 500mg/m2 q.6weekly.
Treatment with nivolumab will continue every 14-days, and pemetrexed treatment will continue every 42-days.
Treatment continues until disease progression or toxicity resulting in treatment discontinuation or until 2 years of treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Feasibility
Time Frame: 1 year after enrollment of last participant
|
The number of participants who complete at least 2 cycles of combination nivolumab with pemetrexed for the treatment of advanced head and neck cancers, over the total duration of study.
|
1 year after enrollment of last participant
|
Safety/tolerability (incidence of adverse events including immune related)
Time Frame: Through study completion up to 2 years
|
Treatment related and non-related adverse events per CTCAE v.4.0.3 of nivolumab with pemetrexed for the treatment of advanced head and neck cancers.
Incidence of adverse events, the number of dose modifications and discontinuations due to adverse events including immune-related adverse events.
|
Through study completion up to 2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response Rate
Time Frame: 1 year after enrollment of last participant.
|
associated with combination nivolumab/pemetrexed therapy (defined as the proportion of participants achieving either a partial response or a complete response as best-overall response per RECIST criteria 1.1)
|
1 year after enrollment of last participant.
|
Progression free survival
Time Frame: 5 years from final study drug dose.
|
associated with combination nivolumab/pemetrexed therapy (defined as the time between the date of treatment initiation and the date of disease progression or death (whatever the cause, whichever occurs first)
|
5 years from final study drug dose.
|
Overall Survival
Time Frame: 5 years from final study drug dose.
|
associated with combination nivolumab/pemetrexed therapy.
(Defined as the time between the date of treatment initiation and the date of death)
|
5 years from final study drug dose.
|
Patient reported quality of life
Time Frame: Through study completion, up to 2 years.
|
associated with combination nivolumab/pemetrexed therapy (measured utilizing the Edmonton Symptom Assessment Score).
This questionnaire includes six yes/no questions, 10 questions with a scale of 0 (no symptoms) to 10 (at the worst).
|
Through study completion, up to 2 years.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Investigation of the role of CD71+ immature red blood cells in the response to treatment with immunotherapy
Time Frame: 1 year after last study drug dose.
|
In this study the frequency of the CD71+erythrocyte cells' (blood draws at pre-chemo, post-chemo and post immunotherapy) will be measured.
|
1 year after last study drug dose.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Hatim Karachiwala, MD FRCPC, Alberta Health Services - Cross Cancer Institute
Publications and helpful links
General Publications
- Vermorken JB, Mesia R, Rivera F, Remenar E, Kawecki A, Rottey S, Erfan J, Zabolotnyy D, Kienzer HR, Cupissol D, Peyrade F, Benasso M, Vynnychenko I, De Raucourt D, Bokemeyer C, Schueler A, Amellal N, Hitt R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1116-27. doi: 10.1056/NEJMoa0802656.
- Emens LA, Middleton G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol Res. 2015 May;3(5):436-43. doi: 10.1158/2326-6066.CIR-15-0064.
- Pivot X, Raymond E, Laguerre B, Degardin M, Cals L, Armand JP, Lefebvre JL, Gedouin D, Ripoche V, Kayitalire L, Niyikiza C, Johnson R, Latz J, Schneider M. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer. 2001 Sep 1;85(5):649-55. doi: 10.1054/bjoc.2001.2010.
- Gilbert J, Murphy B, Dietrich MS, Henry E, Jordan R, Counsell A, Wirth P, Yarbrough WG, Slebos RJ, Chung CH. Phase 2 trial of oxaliplatin and pemetrexed as an induction regimen in locally advanced head and neck cancer. Cancer. 2012 Feb 15;118(4):1007-13. doi: 10.1002/cncr.26364. Epub 2011 Jul 15.
- Vermorken JB, Licitra L, Stohlmacher-Williams J, Dietz A, Lopez-Picazo JM, Hamid O, Hossain AM, Chang SC, Gauler TC. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer. 2013 Sep;49(13):2877-83. doi: 10.1016/j.ejca.2013.05.002. Epub 2013 May 30.
- Davis M, Conlon K, Bohac GC, Barcenas J, Leslie W, Watkins L, Lamzabi I, Deng Y, Li Y, Plate JM. Effect of pemetrexed on innate immune killer cells and adaptive immune T cells in subjects with adenocarcinoma of the pancreas. J Immunother. 2012 Oct;35(8):629-40. doi: 10.1097/CJI.0b013e31826c8a4f.
- Elahi S, Ertelt JM, Kinder JM, Jiang TT, Zhang X, Xin L, Chaturvedi V, Strong BS, Qualls JE, Steinbrecher KA, Kalfa TA, Shaaban AF, Way SS. Immunosuppressive CD71+ erythroid cells compromise neonatal host defence against infection. Nature. 2013 Dec 5;504(7478):158-62. doi: 10.1038/nature12675. Epub 2013 Nov 6.
- Dunsmore G, Bozorgmehr N, Delyea C, Koleva P, Namdar A, Elahi S. Erythroid Suppressor Cells Compromise Neonatal Immune Response against Bordetella pertussis. J Immunol. 2017 Sep 15;199(6):2081-2095. doi: 10.4049/jimmunol.1700742. Epub 2017 Aug 4.
- Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982 Dec;5(6):649-55. No abstract available.
- Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbe C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24.
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Neoplasms, Squamous Cell
- Carcinoma, Squamous Cell
- Molecular Mechanisms of Pharmacological Action
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Immunological
- Immune Checkpoint Inhibitors
- Folic Acid Antagonists
- Nivolumab
- Pemetrexed
Other Study ID Numbers
- Nivo Plus: IIT-0009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SCCHN
-
Peking UniversityBiotech Pharmaceutical Co., Ltd.Unknown
-
NanoCarrier Co., Ltd.Orient Europharma Co., Ltd.RecruitingSCCHNCroatia, Czechia, Hungary, Poland, Russian Federation, Serbia, Taiwan, Ukraine
-
University Hospital, CaenUnknown
-
UNICANCERBristol-Myers SquibbCompletedRecurrent and/or Metastatic Platinum-refractory SCCHNFrance
-
Stanford UniversityNational Cancer Institute (NCI)CompletedSquamous Neck Carcinoma of the Head and Neck Cancer (SCCHN)United States
-
University of Alabama at BirminghamActive, not recruiting
-
Merck KGaA, Darmstadt, GermanyMerck Ltd., IndiaTerminatedUnresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck | LA SCCHNIndia
-
Massachusetts General HospitalDana-Farber Cancer Institute; Genentech, Inc.; Emory University; University of... and other collaboratorsTerminatedSquamous Cell Carcinoma of the Head and Neck (SCCHN)United States
-
PfizerCompletedSquamous Cell Carcinoma of the Head and Neck (SCCHN)United States, Spain, Korea, Republic of, Czechia, Taiwan, Serbia, Japan, Slovakia, Mexico, Romania, Hungary, Italy, Poland, Russian Federation, Ukraine
-
PfizerEMD Serono; Astellas Pharma Inc; Nektar TherapeuticsTerminatedSquamous Cell Carcinoma of the Head and Neck (SCCHN) | Metastatic Castration Resistant Prostate Cancer (mCRPC)Spain, United States, Poland, Belgium
Clinical Trials on Combination Product: Nivolumab with Pemetrexed
-
Threshold PharmaceuticalsEMD SeronoTerminatedNon-small Cell Lung CancerUnited States, Germany, Spain, Poland, Greece, Czechia, Hungary, Italy, Romania, Russian Federation
-
HUYABIO International, LLC.Bristol-Myers SquibbRecruitingUnresectable or Metastatic Melanoma | Progressive Brain MetastasisSpain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
-
Sidney Kimmel Comprehensive Cancer Center at Johns...Bristol-Myers SquibbActive, not recruitingBladder Cancer | Urothelial CarcinomaUnited States
-
PfizerTerminatedNon-small Cell Lung Cancer | Urothelial CancerSpain, Czechia, United States, Australia, United Kingdom, Italy, Canada, Hungary
-
Second Affiliated Hospital, School of Medicine,...Recruiting
-
ViaCyteCalifornia Institute for Regenerative Medicine (CIRM)TerminatedType 1 Diabetes MellitusCanada, United States
-
Clinica Universidad de Navarra, Universidad de...Highlight TherapeuticsRecruitingNon-Small Cell Lung Cancer MetastaticSpain
-
Nektar TherapeuticsBristol-Myers SquibbCompletedMelanoma | Renal Cell Carcinoma | Gastric Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Urothelial Carcinoma | HR+/HER2- Breast CancerUnited States, Spain, Canada, France, Italy, Belgium, Poland, United Kingdom
-
ViaCyteCalifornia Institute for Regenerative Medicine (CIRM); Horizon 2020 - European...CompletedType 1 Diabetes Mellitus With HypoglycemiaUnited States, Canada, Belgium
-
ViaCyteTerminatedType 1 DiabetesUnited States